Open questions

This page enumerates analytic questions where primary-source evidence is currently incomplete and where additional research could materially update the COHR thesis. Each question is rated by importance (low / medium / high — to thesis-conviction) and resolvability (high if specific filings will surface answers; low if structurally confidential or aggregator-only). Confidence flags follow the standard ✓ · ◐ · ⚠ schema.

High-importance / high-resolvability (priority research)

Q1 — What is the dollar-scale of the NVDA multi-billion-dollar purchase commitment?

Confidence: ⚠ Not disclosed in 8-K or partnership press release.

Why it matters: The NVDA purchase commitment underwrites a meaningful share of Coherent’s FY2027–FY2028 D&C capacity. The dollar-scale (e.g., $5B over 3 years vs $10B over 5 years) materially affects the bull-case revenue trajectory and capacity-utilization math.

Resolution path: Future 10-Q / 10-K filings may disclose minimum-purchase-commitment language; quarterly earnings commentary may surface scope detail; NVDA-Coherent supplementary agreements (if filed publicly) would be definitive.

Cross-link: Bull case pillar 1; 03_ecosystem NVIDIA partnership

Q2 — What is Coherent’s NVDA-direct revenue contribution as of Q3 FY2026?

Confidence: ⚠ Not separately disclosed.

Why it matters: Customer-concentration risk depends on NVDA’s share of revenue. Estimates range from 15% to 35% of D&C revenue depending on assumptions; the actual figure is the load-bearing input for concentration-risk analysis.

Resolution path: 10-K customer-concentration disclosure (annual filing); management commentary on quarterly calls; 10-Q segment-disclosure ratios.

Cross-link: Risks R1; Bear case pillar 1

Q3 — What is the outstanding face / converted balance of the Series B Convertible Preferred Stock as of Q3 FY2026?

Confidence: ⚠ Q3 FY2026 disclosure pending; partial disclosures available in earlier 10-Qs.

Why it matters: Series B is up to $2B authorized, held by Bain Capital alone via the BCPE Watson SPV (NOT Senator Investment Group). PIK accretion through November 20, 2025 grew the as-converted base; the outstanding face at the $85.00 conversion strike determines incremental dilution and conversion-overhang severity.

Resolution path: Q3 FY2026 10-Q (expected May 2026); Bain Capital 13G/13D amendments via BCPE Watson; specific 8-Ks on conversion events.

Cross-link: 05_financials balance sheet; Risks R8

Q4 — What is the specific Q3 FY2026 capex level, and is the Sherman TX 6-inch InP fab capacity-doubling target on schedule for Q4 CY2026?

Confidence: ◐ Q1 FY2026 commentary indicated ~80% of target wafer-start rate.

Why it matters: The 6-inch InP cost-advantage thesis depends on capacity-doubling on schedule. Slip would compress the FY2027 EML supply expansion narrative.

Resolution path: Q3 FY2026 earnings (expected May 6, 2026); Q4 FY2026 earnings (expected August 2026); specific milestone disclosures.

Cross-link: 05_financials capex cycle; 04_market InP EML duopoly

Q5 — What is the FY2026 segment-margin profile (Datacenter & Communications vs Industrial) at the operating-margin level?

Confidence: ⚠ Coherent does not disclose segment OM at a granular level.

Why it matters: Knowing the OM differential between D&C and Industrial enables more precise mix-shift modeling and quantification of the Industrial-segment drag on consolidated OM.

Resolution path: 10-K disclosures may include segment OM detail; alternative: management commentary on relative profitability; analyst questions on earnings calls.

Cross-link: 05_financials margins and pricing; 05_financials segment revenue mix

High-importance / low-resolvability (structural uncertainty)

Q6 — When does CPO commercial-volume actually start (vs published 2027 / 2028 timeline)?

Confidence: ⚠ Industry-consensus 2027/2028; historical timelines have slipped.

Why it matters: CPO is a material future revenue category for Coherent. 12-24-month slip from current timeline would compress FY2028+ revenue trajectory.

Resolution path: Hard-to-resolve in advance; tracked through OFC trade-show progress, NVDA quarterly Spectrum-X / Quantum-X commentary, Coherent CPO-product disclosures, hyperscaler procurement RFPs.

Cross-link: 04_market CPO market; Catalysts C8

Q7 — Does NVDA in-source InP source lasers post-CY2028?

Confidence: ⚠ No public signal as of April 2026; bilateral $4B equity commitment is consistent with merchant-supply preference through 2028.

Why it matters: NVDA in-sourcing is the single most thesis-breaking scenario. Determining the probability requires reading NVDA’s strategic intent over a 3+ year horizon, which is structurally uncertain.

Resolution path: Long-term watch; signals would include NVDA fab-investment announcements, M&A activity, or material reduction in NVDA-Coherent / NVDA-Lumentum commitments.

Cross-link: Bear case pillar 3; Risks R1

Q8 — Will hyperscalers procure CPO directly (separate from NVDA’s switch business) by 2028?

Confidence: ⚠ Currently a 2028+ scenario; depends on hyperscaler architecture decisions.

Why it matters: Hyperscaler-direct CPO procurement would multiply Coherent’s CPO TAM beyond NVDA-direct.

Resolution path: Hyperscaler procurement RFP signals; analyst commentary; specific Coherent customer-win disclosures.

Cross-link: 04_market CPO market; Catalysts C11

Medium-importance questions

Confidence: ⚠ Aggregator estimates vary widely; some forecasts have LPO at 15–25% of 1.6T volume by 2028, others lower.

Why it matters: LPO/OBO penetration is the structural alternative-architecture risk to CPO. High LPO penetration delays CPO; this affects Coherent’s CPO-revenue trajectory.

Resolution path: Industry trade-press; OFC trade-show signals; Coherent / Lumentum commentary on competing-architecture adoption.

Cross-link: 04_market CPO market; 04_market datacenter optics TAM

Q10 — Will Coherent divest the remaining 75% of Silicon Carbide LLC?

Confidence: ⚠ Analyst speculation; no announcement.

Why it matters: A SiC-business divestiture would crystallize value (DENSO + Mitsubishi paid $1B for 25% in 2023, implying ~$3B value for the 75%). Counter-argument: keeps Coherent diversified into power electronics with EV-secular tailwind.

Resolution path: Strategic review announcements; financial-disclosure structures around Silicon Carbide LLC; management commentary on portfolio-rationalization.

Cross-link: 04_market SiC market; 05_financials segment revenue mix

Q11 — What is Bain Capital’s (BCPE Watson SPV) total cumulative Coherent position as of April 2026, and what is their planned exit horizon?

Confidence: ⚠ Public 13G/13D filings via BCPE Watson SPV give updates; specific exit-horizon is non-public.

Why it matters: Bain Capital is the sole holder of the Series B Convertible Preferred (Senator Investment Group is NOT a holder). A large Bain position rotation could pressure stock price; conversely, the November 2025 dividend waiver — which sacrificed both ongoing PIK accretion and the post-year-four cash-pay step — suggests a long-term equity-conviction hold. Position sizing affects share-count and capital-structure clarity.

Resolution path: BCPE Watson 13G/13D amendments; specific 8-Ks on share dispositions or conversion elections; periodic regulatory filings.

Cross-link: 05_financials balance sheet; 05_financials Coherent Inc. integration

Q12 — What is the realistic FY2028 NVDA-customer concentration (% of D&C revenue and consolidated revenue)?

Confidence: ◐ Inferable from purchase-commitment scope (when known) and NVDA’s share of merchant optical demand.

Why it matters: Concentration mathematics is central to the bear-pillar-1 risk evaluation.

Resolution path: Annual 10-K customer-concentration disclosures; quarterly earnings call commentary; cross-validation from NVDA-side capex disclosures.

Cross-link: Bear case pillar 1; Risks R1

Low-importance / structural-uncertainty questions

Q13 — How quickly does Industrial segment recover, and to what level?

Confidence: ⚠ Cyclical-economy-dependent; 2026–2027 trajectory uncertain.

Why it matters: Industrial recovery affects consolidated growth rate (modestly) but is not thesis-altering.

Cross-link: 04_market industrial laser market; 05_financials segment revenue mix

Q14 — Will Coherent enter additional ASIC / DSP partnerships beyond Marvell?

Confidence: ⚠ Speculative; based on ecosystem-positioning analysis.

Why it matters: DSP/ASIC partnerships affect transceiver competitiveness vs Innolight / Eoptolink Chinese competition.

Cross-link: 03_ecosystem foundry partners; MRVL

Q15 — What is the realistic ASP path for 200G EML chips in CY2026–CY2027?

Confidence: ⚠ Trade-press / analyst-house estimates (“double-digit ASP increases CY2026”); precise figures are confidential.

Why it matters: ASP assumption is a key input for revenue + margin modeling.

Resolution path: Trade-press analysis; aggregator commentary; cross-validation with Lumentum margin behavior.

Cross-link: 05_financials margins and pricing; 04_market InP EML duopoly

Research-priority summary

Priority tier	Questions	Resolution timing
Tier 1 — must-resolve for thesis	Q1, Q2, Q3, Q4, Q5	Q3 FY2026 10-Q (May 2026); Q4 FY2026 10-K (Aug 2026); next earnings calls
Tier 2 — material updates if resolved	Q6, Q7, Q8, Q9, Q12	Multi-year horizon; qualitative signal-watching
Tier 3 — nice-to-resolve	Q10, Q11, Q13, Q14, Q15	Opportunistic / aggregator-driven

Cross-link

Bull case, Bear case, Risks
Catalysts — events that resolve questions
Cross-thesis implications
05_financials DCF assumptions, earnings calls

Sources

Coherent SEC filings (annual + quarterly) accessible via EDGAR ✓
All sources documented across the 04_market and 05_financials sections.